Cargando…

Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument

BACKGROUND: Currently, there is no patient-reported outcome (PRO) instrument specifically designed to evaluate hypertrophic cardiomyopathy (HCM). OBJECTIVE: We present the development and psychometric validation of a novel PRO measure, the HCM Symptom Questionnaire version 1.0 (HCMSQv1.0). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Reaney, Matthew, Allen, Veleka, Sehnert, Amy J., Fang, Liang, Hagège, Albert A., Naidu, Srihari S., Olivotto, Iacopo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283619/
https://www.ncbi.nlm.nih.gov/pubmed/35653062
http://dx.doi.org/10.1007/s41669-022-00335-5
_version_ 1784747364579278848
author Reaney, Matthew
Allen, Veleka
Sehnert, Amy J.
Fang, Liang
Hagège, Albert A.
Naidu, Srihari S.
Olivotto, Iacopo
author_facet Reaney, Matthew
Allen, Veleka
Sehnert, Amy J.
Fang, Liang
Hagège, Albert A.
Naidu, Srihari S.
Olivotto, Iacopo
author_sort Reaney, Matthew
collection PubMed
description BACKGROUND: Currently, there is no patient-reported outcome (PRO) instrument specifically designed to evaluate hypertrophic cardiomyopathy (HCM). OBJECTIVE: We present the development and psychometric validation of a novel PRO measure, the HCM Symptom Questionnaire version 1.0 (HCMSQv1.0). METHODS: Cognitive debriefing interviews and a card-sorting task were conducted in 33 patients with HCM to support development of the HCMSQv1.0, showing the scale to be interpretable and relevant to patients’ experiences. Baseline blinded data from two trials (EXPLORER-HCM and MAVERICK-HCM) were pooled (N = 299) to develop the scoring algorithm of HCMSQv1.0. Measurement properties were examined, followed by a meaningful-change analysis to interpret scores. Rasch modeling, mixed-model repeated measures, exploratory factor analysis, confirmatory factor analysis, and missing-data simulation analysis informed the number of domains and the items in each domain. RESULTS: The scoring algorithm for HCMSQv1.0 consists of four domains: shortness of breath, tiredness, cardiovascular symptoms, and syncope; plus a total score, with higher scores indicating more severe symptoms. Item characteristics, internal consistency, test–retest reliability, construct validity, and responsiveness were acceptable. A clinically meaningful responder definition of 1–2 points on the HCMSQv1.0 score for shortness of breath and total score, and approximately 1 point on the tiredness and cardiovascular symptom scores, was calculated based on distribution- and anchor-based methods. CONCLUSION: Our findings support the HCMSQv1.0 as a fit-for-purpose PRO instrument for assessing treatment benefit in patients with HCM. Studies in larger patient populations are ongoing to confirm responder definition and scoring approaches encompassing key HCM symptoms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-022-00335-5.
format Online
Article
Text
id pubmed-9283619
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92836192022-07-16 Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument Reaney, Matthew Allen, Veleka Sehnert, Amy J. Fang, Liang Hagège, Albert A. Naidu, Srihari S. Olivotto, Iacopo Pharmacoecon Open Original Research Article BACKGROUND: Currently, there is no patient-reported outcome (PRO) instrument specifically designed to evaluate hypertrophic cardiomyopathy (HCM). OBJECTIVE: We present the development and psychometric validation of a novel PRO measure, the HCM Symptom Questionnaire version 1.0 (HCMSQv1.0). METHODS: Cognitive debriefing interviews and a card-sorting task were conducted in 33 patients with HCM to support development of the HCMSQv1.0, showing the scale to be interpretable and relevant to patients’ experiences. Baseline blinded data from two trials (EXPLORER-HCM and MAVERICK-HCM) were pooled (N = 299) to develop the scoring algorithm of HCMSQv1.0. Measurement properties were examined, followed by a meaningful-change analysis to interpret scores. Rasch modeling, mixed-model repeated measures, exploratory factor analysis, confirmatory factor analysis, and missing-data simulation analysis informed the number of domains and the items in each domain. RESULTS: The scoring algorithm for HCMSQv1.0 consists of four domains: shortness of breath, tiredness, cardiovascular symptoms, and syncope; plus a total score, with higher scores indicating more severe symptoms. Item characteristics, internal consistency, test–retest reliability, construct validity, and responsiveness were acceptable. A clinically meaningful responder definition of 1–2 points on the HCMSQv1.0 score for shortness of breath and total score, and approximately 1 point on the tiredness and cardiovascular symptom scores, was calculated based on distribution- and anchor-based methods. CONCLUSION: Our findings support the HCMSQv1.0 as a fit-for-purpose PRO instrument for assessing treatment benefit in patients with HCM. Studies in larger patient populations are ongoing to confirm responder definition and scoring approaches encompassing key HCM symptoms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-022-00335-5. Springer International Publishing 2022-06-02 /pmc/articles/PMC9283619/ /pubmed/35653062 http://dx.doi.org/10.1007/s41669-022-00335-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Reaney, Matthew
Allen, Veleka
Sehnert, Amy J.
Fang, Liang
Hagège, Albert A.
Naidu, Srihari S.
Olivotto, Iacopo
Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
title Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
title_full Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
title_fullStr Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
title_full_unstemmed Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
title_short Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
title_sort development of the hypertrophic cardiomyopathy symptom questionnaire (hcmsq): a new patient-reported outcome (pro) instrument
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283619/
https://www.ncbi.nlm.nih.gov/pubmed/35653062
http://dx.doi.org/10.1007/s41669-022-00335-5
work_keys_str_mv AT reaneymatthew developmentofthehypertrophiccardiomyopathysymptomquestionnairehcmsqanewpatientreportedoutcomeproinstrument
AT allenveleka developmentofthehypertrophiccardiomyopathysymptomquestionnairehcmsqanewpatientreportedoutcomeproinstrument
AT sehnertamyj developmentofthehypertrophiccardiomyopathysymptomquestionnairehcmsqanewpatientreportedoutcomeproinstrument
AT fangliang developmentofthehypertrophiccardiomyopathysymptomquestionnairehcmsqanewpatientreportedoutcomeproinstrument
AT hagegealberta developmentofthehypertrophiccardiomyopathysymptomquestionnairehcmsqanewpatientreportedoutcomeproinstrument
AT naidusriharis developmentofthehypertrophiccardiomyopathysymptomquestionnairehcmsqanewpatientreportedoutcomeproinstrument
AT olivottoiacopo developmentofthehypertrophiccardiomyopathysymptomquestionnairehcmsqanewpatientreportedoutcomeproinstrument